Company and Industry Overview * **Company**: Viatris Inc. (NASDAQ: VTRS) * **Industry**: Pharmaceuticals, Healthcare Key Points and Arguments 1. **Strategic Pillars**: * **Diversified and Growing Base Business**: Demonstrated year-over-year operational adjusted revenue growth for six consecutive quarters, driven by both brands and generics. [4] * **Innovative Pipeline**: Executing clinical trials for selatogrel and cenerimod, and entered into an exclusive licensing agreement with Lexicon for sotagliflozin. [8] * **Capital Allocation**: 50% for business development, 25% for share repurchases, and 25% for dividends. [17] 2. **Financial Performance**: * Generated strong free cash flow of $866 million in Q3, bringing year-to-date cash flow generation to $1.9 billion. [7] * Repurchased about $1.9 billion of debt in Q3. [6] * Confident in generating $2.3 billion of cash flow on an ongoing basis. [7] 3. **New Product Revenue**: * On track to achieve $500 million to $600 million of new product revenue for the year. [5] * Pipeline includes generic launches in North America and Europe, as well as key complex generics like glucagon, liraglutide, and iron sucrose. [12] 4. **Regulatory Updates**: * Nearing the end of regulatory processes for sandostatin LAR, liraglutide, and iron sucrose. [14] * Meeting with FDA for GA Depot in December. [14] 5. **Capital Allocation Strategy**: * 50% of free cash flow allocated to business development, focusing on supporting the base business and adding innovative assets. [24] * Disciplined approach to evaluating business development opportunities, considering strategic fit, commercial potential, and financial impact. [29] 6. **Therapeutic Areas of Focus**: * Ophthalmology, GI, dermatology, cardiovascular, and immunology. [53] 7. **Geographical Focus**: * Europe, Greater China, emerging markets, and JANZ. [55] Additional Important Points * Viatris has a strong global footprint and expertise in both brands and generics. [55] * The company is focused on leveraging its existing infrastructure and capabilities to drive growth. [24] * Viatris is committed to being disciplined and thoughtful in its approach to business development. [29]

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups prior to co-founding 1200 Pharma at the California Institute of Technology (Caltech, 2016).-Became the first employee of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures)-Remains an avid investor, focused on market trends and especially biotechnology stocks ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other j ...

Viatris Inc. (VTRS) delivered third-quarter 2024 adjusted earnings of 75 cents per share, which beat the Zacks Consensus Estimate of 68 cents. The company recorded adjusted earnings of 79 cents per share in the year-ago quarter.Total revenues came in at $3.75 billion, down 4.8% year over year. Revenues included product sales and other revenues. The top line beat the Zacks Consensus Estimate of $3.68 billion.VTRS’ shares have risen 7.2% year to date against the industry’s 5.1% decline.Image Source: Zacks Inv ...

Q3 2024 Earnings November 7, 2024 1 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2024 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform A ...

Viatris Inc. (NASDAQ:VTRS) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants Glen Santangelo - Jefferies Jason Gerberry - Bank of America Ethan Brown - JPMorgan Ashwani Verma - UBS David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning, everyone, and welcome to the V ...

For the quarter ended September 2024, Viatris (VTRS) reported revenue of $3.75 billion, down 4.8% over the same period last year. EPS came in at $0.75, compared to $0.78 in the year-ago quarter. The reported revenue represents a surprise of +1.89% over the Zacks Consensus Estimate of $3.68 billion. With the consensus EPS estimate being $0.68, the EPS surprise was +10.29%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

Viatris (VTRS) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.29%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.68 per share when it actually produced earnings of $0.69, delivering a surprise of 1.47%.Over the last four quarters, the company ...

Viatris Reports Third Quarter Financial Results for 2024 • Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] • Strong New Product Revenues of $133 Million Drove Growth Across Segments • U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a DivestitureAdjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted ...

PITTSBURGH, Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024.About Viatris Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between gener ...